Christian M Hedrich

List of Publications by Year
in descending order

154 papers	6,637 citations	44042 48 h-index	76872 74 g-index
180 all docs	180 docs citations	180 times ranked	7336 citing authors

#	Article	IF	Citations
1	COVID-19: Immunology and treatment options. Clinical Immunology, 2020, 215, 108448.	1.4	485
2	CaMK4-dependent activation of AKT/mTOR and CREM-Î± underlies autoimmunity-associated Th17 imbalance. Journal of Clinical Investigation, 2014, 124, 2234-2245.	3.9	185
3	Cell type-specific regulation of IL-10 expression in inflammation and disease. Immunologic Research, 2010, 47, 185-206.	1.3	180
4	Chronic Recurrent Multifocal Osteomyelitis (CRMO): Presentation, Pathogenesis, and Treatment. Current Osteoporosis Reports, 2017, 15, 542-554.	1.5	171
5	The Role of Epigenetics in Autoimmune/Inflammatory Disease. Frontiers in Immunology, 2019, 10, 1525.	2.2	161
6	Autoinflammatory bone disorders with special focus on chronic recurrent multifocal osteomyelitis (CRMO). Pediatric Rheumatology, 2013, 11, 47.	0.9	155
7	Epigenetic mechanisms in systemic lupus erythematosus and other autoimmune diseases. Trends in Molecular Medicine, 2011, 17, 714-724.	3.5	154
8	Biological properties and regulation of IL-10 related cytokines and their contribution to autoimmune disease and tissue injury. Clinical Immunology, 2012, 143, 116-127.	1.4	149
9	Stat3 promotes IL-10 expression in lupus T cells through trans- activation and chromatin remodeling. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 13457-13462.	3.3	148
10	Distinct interferon signatures and cytokine patterns define additional systemic autoinflammatory diseases. Journal of Clinical Investigation, 2020, 130, 1669-1682.	3.9	142
11	Consensus Treatment Plans for Chronic Nonbacterial Osteomyelitis Refractory to Nonsteroidal Antiinflammatory Drugs and/or With Active Spinal Lesions. Arthritis Care and Research, 2018, 70, 1228-1237.	1.5	128
12	cAMP-responsive Element Modulator (CREM)Î± Protein Induces Interleukin 17A Expression and Mediates Epigenetic Alterations at the Interleukin-17A Gene Locus in Patients with Systemic Lupus Erythematosus. Journal of Biological Chemistry, 2011, 286, 43437-43446.	1.6	122
13	Chilblain lupus erythematosusâ€"a review of literature. Clinical Rheumatology, 2008, 27, 949-954.	1.0	101
14	Unexpectedly high incidences of chronic non-bacterial as compared to bacterial osteomyelitis in children. Rheumatology International, 2016, 36, 1737-1745.	1.5	101
15	Gene-function studies in systemic lupus erythematosus. Nature Reviews Rheumatology, 2013, 9, 476-484.	3.5	99
16	Treatment Response and Longterm Outcomes in Children with Chronic Nonbacterial Osteomyelitis. Journal of Rheumatology, 2017, 44, 1058-1065.	1.0	99
17	Attenuated TLR4/MAPK signaling in monocytes from patients with CRMO results in impaired IL-10 expression. Clinical Immunology, 2012, 145, 69-76.	1.4	97
18	TCRÎ±Î² + CD3 + CD4 â^' CD8 â^' (double negative) T cells in autoimmunity. Autoimmunity Reviews, 2018, 17, 422-430.	2.5	94

#	Article	IF	Citations
19	Juvenile-onset systemic lupus erythematosus: Update on clinical presentation, pathophysiology and treatment options. Clinical Immunology, 2019, 209, 108274.	1.4	94
20	cAMP response element modulator Î± controls IL2 and IL17A expression during CD4 lineage commitment and subset distribution in lupus. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 16606-16611.	3.3	92
21	Chronic non-bacterial osteomyelitis is associated with impaired Sp1 signaling, reduced IL10 promoter phosphorylation, and reduced myeloid IL-10 expression. Clinical Immunology, 2011, 141, 317-327.	1.4	91
22	The Catalytic Subunit of Protein Phosphatase 2A (PP2Ac) Promotes DNA Hypomethylation by Suppressing the Phosphorylated Mitogen-activated Protein Kinase/Extracellular Signal-regulated Kinase (ERK) Kinase (MEK)/Phosphorylated ERK/DNMT1 Protein Pathway in T-cells from Controls and Systemic Lupus Erythematosus Patients. Journal of Biological Chemistry, 2013, 288, 21936-21944.	1.6	91
23	Altered expression of IL-10 family cytokines in monocytes from CRMO patients result in enhanced IL-1Î² expression and release. Clinical Immunology, 2015, 161, 300-307.	1.4	88
24	Autoinflammatory bone disorders. Clinical Immunology, 2013, 147, 185-196.	1.4	86
25	DNA methylation in systemic lupus erythematosus. Epigenomics, 2017, 9, 505-525.	1.0	86
26	Chronic Nonbacterial Osteomyelitis: Pathophysiological Concepts and Current Treatment Strategies. Journal of Rheumatology, 2016, 43, 1956-1964.	1.0	84
27	SARS-CoV-2 infections in children and young people. Clinical Immunology, 2020, 220, 108588.	1.4	82
28	cAMP-responsive Element Modulator (CREM)Î± Protein Signaling Mediates Epigenetic Remodeling of the Human Interleukin-2 Gene. Journal of Biological Chemistry, 2011, 286, 43429-43436.	1.6	81
29	Epigenetics in SLE. Current Rheumatology Reports, 2017, 19, 58.	2.1	79
30	cAMP responsive element modulator: a critical regulator of cytokine production. Trends in Molecular Medicine, 2013, 19, 262-269.	3.5	77
31	Protein Phosphatase 2A Enables Expression of Interleukin 17 (IL-17) through Chromatin Remodeling. Journal of Biological Chemistry, 2013, 288, 26775-26784.	1.6	77
32	Shaping the spectrum â€" From autoinflammation to autoimmunity. Clinical Immunology, 2016, 165, 21-28.	1.4	76
33	Practice and consensus-based strategies in diagnosing and managing systemic juvenile idiopathic arthritis in Germany. Pediatric Rheumatology, 2018, 16, 7.	0.9	72
34	The German National Registry of Primary Immunodeficiencies (2012â€"2017). Frontiers in Immunology, 2019, 10, 1272.	2.2	71
35	cAMP Responsive Element Modulator (CREM) Î± Mediates Chromatin Remodeling of CD8 during the Generation of CD3+CD4â^'CD8â^' T Cells. Journal of Biological Chemistry, 2014, 289, 2361-2370.	1.6	66
36	Stat4-dependent, T-bet-independent regulation of IL-10 in NK cells. Genes and Immunity, 2008, 9, 316-327.	2.2	65

#	Article	IF	Citations
37	Update: Cytokine Dysregulation in Chronic Nonbacterial Osteomyelitis (CNO). International Journal of Rheumatology, 2012, 2012, 1-7.	0.9	65
38	Increased Expression of SLAM Receptors SLAMF3 and SLAMF6 in Systemic Lupus Erythematosus T Lymphocytes Promotes Th17 Differentiation. Journal of Immunology, 2012, 188, 1206-1212.	0.4	65
39	Systemic Lupus Erythematosus in Children and Young People. Current Rheumatology Reports, 2021, 23, 20.	2.1	64
40	Juvenile-onset systemic lupus erythematosus (jSLE) â€“ Pathophysiological concepts and treatment options. Best Practice and Research in Clinical Rheumatology, 2017, 31, 488-504.	1.4	62
41	Clinical and laboratory characteristics in juvenile-onset systemic lupus erythematosus across age groups. Lupus, 2020, 29, 474-481.	0.8	62
42	cAMP-responsive Element Modulator Î± (CREMÎ±) Suppresses IL-17F Protein Expression in T Lymphocytes from Patients with Systemic Lupus Erythematosus (SLE). Journal of Biological Chemistry, 2012, 287, 4715-4725.	1.6	61
43	Serum biomarkers for the diagnosis and monitoring of chronic recurrent multifocal osteomyelitis (CRMO). Rheumatology International, 2016, 36, 769-779.	1.5	61
44	Current understanding of the pathophysiology of systemic juvenile idiopathic arthritis (sJIA) and target-directed therapeutic approaches. Clinical Immunology, 2015, 159, 72-83.	1.4	60
45	Epigenetic regulation of cytokine expression in systemic lupus erythematosus with special focus on T cells. Autoimmunity, 2014, 47, 234-241.	1.2	59
46	New Insights into Adult and Paediatric Chronic Non-bacterial Osteomyelitis CNO. Current Rheumatology Reports, 2020, 22, 52.	2.1	57
47	Presentation, Treatment Response and Short-Term Outcomes in Paediatric Multisystem Inflammatory Syndrome Temporally Associated with SARS-CoV-2 (PIMS-TS). Journal of Clinical Medicine, 2020, 9, 3293.	1.0	56
48	Kawasaki Disease. Frontiers in Pediatrics, 2018, 6, 198.	0.9	54
49	cAMP-responsive Element Modulator Î± (CREMÎ±) trans-Represses the Transmembrane Glycoprotein CD8 and Contributes to the Generation of CD3+CD4â^'CD8â^' T Cells in Health and Disease. Journal of Biological Chemistry, 2013, 288, 31880-31887.	1.6	53
50	Autoinflammatory mutation in NLRC4 reveals a leucine-rich repeat (LRR)â€“LRR oligomerization interface. Journal of Allergy and Clinical Immunology, 2018, 142, 1956-1967.e6.	1.5	52
51	A clinical and pathomechanistic profile of chronic nonbacterial osteomyelitis/chronic recurrent multifocal osteomyelitis and challenges facing the field. Expert Review of Clinical Immunology, 2013, 9, 845-854.	1.3	49
52	Novel paediatric presentation of COVID-19 with ARDS and cytokine storm syndrome without respiratory symptoms. Lancet Rheumatology, The, 2020, 2, e376-e379.	2.2	49
53	COVID-19 â€“ Considerations for the paediatric rheumatologist. Clinical Immunology, 2020, 214, 108420.	1.4	49
54	Chronic nonbacterial osteomyelitis (CNO) and chronic recurrent multifocal osteomyelitis (CRMO). Journal of Translational Autoimmunity, 2021, 4, 100095.	2.0	48

#	Article	IF	Citations
55	Childhood Vasculitis. Frontiers in Pediatrics, 2018, 6, 421.	0.9	45
56	A humanIL10BAC transgene reveals tissue-specific control of IL-10 expression and alters disease outcome. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 17123-17128.	3.3	44
57	cAMP-responsive Element Modulator Î± (CREMÎ±) Contributes to Decreased Notch-1 Expression in T Cells from Patients with Active Systemic Lupus Erythematosus (SLE). Journal of Biological Chemistry, 2012, 287, 42525-42532.	1.6	44
58	Anakinra: A safe and effective first-line treatment in systemic onset juvenile idiopathic arthritis (SoJIA). Rheumatology International, 2012, 32, 3525-3530.	1.5	41
59	TCR + CD3 + CD4 â^' CD8 â^' effector T cells in psoriasis. Clinical Immunology, 2017, 181, 51-59.	1.4	39
60	The molecular pathophysiology of chronic non-bacterial osteomyelitis (CNO)â€"a systematic review. Molecular and Cellular Pediatrics, 2017, 4, 7.	1.0	39
61	Pilot study: possible association of IL10 promoter polymorphisms with CRMO. Rheumatology International, 2012, 32, 555-556.	1.5	38
62	COVID-19 in children and young people. Lancet Rheumatology, The, 2020, 2, e514-e516.	2.2	35
63	CD14+ monocytes contribute to inflammation in chronic nonbacterial osteomyelitis (CNO) through increased NLRP3 inflammasome expression. Clinical Immunology, 2018, 196, 77-84.	1.4	33
64	Outcomes following mycophenolate mofetil versus cyclophosphamide induction treatment for proliferative juvenile-onset lupus nephritis. Lupus, 2019, 28, 613-620.	0.8	33
65	Innately Adaptive or Truly Autoimmune: Is There Something Unique About Systemic Juvenile Idiopathic Arthritis?. Arthritis and Rheumatology, 2020, 72, 210-219.	2.9	33
66	The Molecular Pathophysiology of Psoriatic Arthritisâ€"The Complex Interplay Between Genetic Predisposition, Epigenetics Factors, and the Microbiome. Frontiers in Molecular Biosciences, 2021, 8, 662047.	1.6	29
67	Serum Interleukin-6 and CCL11/Eotaxin May Be Suitable Biomarkers for the Diagnosis of Chronic Nonbacterial Osteomyelitis. Frontiers in Pediatrics, 2017, 5, 256.	0.9	28
68	Dynamic DNA methylation patterns across the mouse and human IL10 genes during CD4+ T cell activation; influence of IL-27. Molecular Immunology, 2010, 48, 73-81.	1.0	27
69	Mechanistic aspects of epigenetic dysregulation in SLE. Clinical Immunology, 2018, 196, 3-11.	1.4	27
70	A panel of urinary proteins predicts active lupus nephritis and response to rituximab treatment. Rheumatology, 2021, 60, 3747-3759.	0.9	26
71	Presentations and Treatment of Childhood Scleroderma: Localized Scleroderma, Eosinophilic Fasciitis, Systemic Sclerosis, and Graft-Versus-Host Disease. Clinical Pediatrics, 2011, 50, 604-614.	0.4	25
72	Early onset systemic lupus erythematosus: differential diagnoses, clinical presentation, and treatment options. Clinical Rheumatology, 2011, 30, 275-283.	1.0	25

#	Article	IF	Citations
73	Chilblain lupus erythematosusâ€"a review of literature. Clinical Rheumatology, 2008, 27, 1341-1341.	1.0	24
74	Clinical and laboratory phenotypes in juvenile-onset Systemic Lupus Erythematosus across ethnicities in the UK. Lupus, 2021, 30, 597-607.	0.8	24
75	CD3-T Cell Receptor Co-stimulation through SLAMF3 and SLAMF6 Receptors Enhances RORÎ³t Recruitment to the IL17A Promoter in Human T Lymphocytes. Journal of Biological Chemistry, 2012, 287, 38168-38177.	1.6	22
76	SLE-Associated Defects Promote Altered T Cell Function. Critical Reviews in Immunology, 2017, 37, 39-58.	1.0	21
77	cAMP Response Element Modulator Î± Induces Dual Specificity Protein Phosphatase 4 to Promote Effector T Cells in Juvenile-Onset Lupus. Journal of Immunology, 2019, 203, 2807-2816.	0.4	21
78	Urine and serum S100A8/A9 and S100A12 associate with active lupus nephritis and may predict response to rituximab treatment. RMD Open, 2020, 6, e001257.	1.8	21
79	Outcome of chronic granulomatous disease â€•Conventional treatment vs stem cell transplantation. Pediatric Allergy and Immunology, 2021, 32, 576-585.	1.1	21
80	Limited sensitivity and specificity of the ACR/EULAR-2019 classification criteria for SLE in JSLE?â€"observations from the UK JSLE Cohort Study. Rheumatology, 2021, 60, 5271-5281.	0.9	21
81	A novel isoform of the orphan receptor RORÎ³t suppresses IL-17 production in human T cells. Genes and Immunity, 2012, 13, 346-350.	2.2	19
82	Bridging the gap between autoinflammation and autoimmunity. Clinical Immunology, 2013, 147, 151-154.	1.4	19
83	Defining consensus opinion to develop randomised controlled trials in rare diseases using Bayesian design: An example of a proposed trial of adalimumab versus pamidronate for children with CNO/CRMO. PLoS ONE, 2019, 14, e0215739.	1.1	19
84	Vasculitis in Juvenile-Onset Systemic Lupus Erythematosus. Frontiers in Pediatrics, 2019, 7, 149.	0.9	19
85	Differential analysis of serum and urine S100 proteins in juvenile-onset systemic lupus erythematosus (jSLE). Clinical Immunology, 2020, 214, 108375.	1.4	19
86	TNF-inhibitors or bisphosphonates in chronic nonbacterial osteomyelitis? - Results of an international retrospective multicenter study. Clinical Immunology, 2022, 238, 109018.	1.4	19
87	Good response to ILâ€1Î² blockade by anakinra in a 23â€yearâ€old CINCA/NOMID patient without mutations in theCIAS1gene. Cytokine profiles and functional studies. Scandinavian Journal of Rheumatology, 2008, 37, 385-389.	0.6	17
88	Cell-Specific Requirements for STAT Proteins and Type I IFN Receptor Signaling Discretely Regulate IL-24 and IL-10 Expression in NK Cells and Macrophages. Journal of Immunology, 2018, 200, 2154-2164.	0.4	17
89	Attainment of low disease activity and remission targets reduces the risk of severe flare and new damage in childhood lupus. Rheumatology, 2022, 61, 3378-3389.	0.9	17
90	Dynamic CpG-DNA Methylation of Il10 and Il19 in CD4+ T Lymphocytes and Macrophages: Effects on Tissue-Specific Gene Expression. Klinische Padiatrie, 2012, 224, 53-60.	0.2	16

#	Article	IF	Citations
91	Neuropsychiatric involvement in juvenile-onset systemic lupus erythematosus: Data from the UK Juvenile-onset systemic lupus erythematosus cohort study. Lupus, 2021, 30, 1955-1965.	0.8	16
92	â€œMutation negativeâ€•familial cold autoinflammatory syndrome (FCAS) in an 8-year-old boy: clinical course and functional studies. Rheumatology International, 2012, 32, 2629-2636.	1.5	15
93	Juvenile Idiopathic Arthritis Associated Uveitis. Children, 2021, 8, 646.	0.6	15
94	Neurotrophin Receptor p75NTR Regulates Immune Function of Plasmacytoid Dendritic Cells. Frontiers in Immunology, 2017, 8, 981.	2.2	14
95	Cardiac pathology and outcomes vary between Kawasaki disease and PIMS-TS. Clinical Immunology, 2021, 229, 108780.	1.4	14
96	Systemic lupus erythematosus â€“ Are children miniature adults?. Clinical Immunology, 2022, 234, 108907.	1.4	14
97	MENINGOENCEPHALITIS CAUSED BY VARICELLA-ZOSTER VIRUS REACTIVATION IN A CHILD WITH DOMINANT PARTIAL INTERFERON-GAMMA RECEPTOR-1 DEFICIENCY. Pediatric Infectious Disease Journal, 2011, 30, 265-266.	1.1	13
98	Epigenetic patterns in systemic sclerosis and their contribution to attenuated CD70 signaling cascades. Clinical Immunology, 2012, 143, 1-3.	1.4	13
99	Enzymatically Inactive Procaspase 1 stabilizes the ASC Pyroptosome and Supports Pyroptosome Spreading during Cell Division. Journal of Biological Chemistry, 2016, 291, 18419-18429.	1.6	13
100	An optimized whole blood assay measuring expression and activity of NLRP3, NLRC4 and AIM2 inflammasomes. Clinical Immunology, 2018, 191, 100-109.	1.4	13
101	Classification of systemic lupus erythematosus in children and adults. Clinical Immunology, 2022, 234, 108898.	1.4	13
102	Diagnosis and Treatment of Angiography Positive Medium to Large Vessel Childhood Primary Angiitis of Central Nervous System (p-cPACNS): An International Survey. Frontiers in Pediatrics, 2021, 9, 654537.	0.9	11
103	DNA Methylation Patterns in CD8+ T Cells Discern Psoriasis From Psoriatic Arthritis and Correlate With Cutaneous Disease Activity. Frontiers in Cell and Developmental Biology, 2021, 9, 746145.	1.8	11
104	Mast cells enhance sterile inflammation in chronic nonbacterial osteomyelitis. DMM Disease Models and Mechanisms, 2019, 12, .	1.2	10
105	Linking genetic variation with epigenetic profiles in SjÃ¶gren's syndrome. Clinical Immunology, 2020, 210, 108314.	1.4	10
106	Genetic Variation and Epigenetic Patterns in Autoimmunity. Journal of Genetic Syndromes & Gene Therapy, 2011, 02, .	0.2	10
107	CASP1 variants influence subcellular caspase-1 localization, pyroptosome formation, pro-inflammatory cell death and macrophage deformability. Clinical Immunology, 2019, 208, 108232.	1.4	9
108	Diagnosis and Treatment of Small Vessel Childhood Primary Angiitis of the Central Nervous System (sv-cPACNS): An International Survey. Frontiers in Pediatrics, 2021, 9, 756612.	0.9	9

#	Article	IF	Citations
109	Panel sequencing links rare, likely damaging gene variants with distinct clinical phenotypes and outcomes in juvenile-onset SLE. Rheumatology, 2023, 62, SI210-SI225.	0.9	9
110	Autosomal Dominant Neurohypophyseal Diabetes Insipidus in Two Families. Hormone Research in Paediatrics, 2009, 71, 111-119.	0.8	8
111	Fluorescent tags influence the enzymatic activity and subcellular localization of procaspase-1. Clinical Immunology, 2015, 160, 172-179.	1.4	8
112	High-dose intravenous methylprednisolone in juvenile non-infectious uveitis: A retrospective analysis. Clinical Immunology, 2020, 211, 108327.	1.4	8
113	The role of epigenetics in paediatric rheumatic disease. Current Opinion in Rheumatology, 2019, 31, 450-463.	2.0	7
114	Establishing core domain sets for Chronic Nonbacterial Osteomyelitis (CNO) and Synovitis, Acne, Pustulosis, Hyperostosis, Osteitis (SAPHO): A report from the OMERACT 2020 special interest group. Seminars in Arthritis and Rheumatism, 2021, 51, 957-961.	1.6	7
115	Lupus IgG deposition causes arthritis but inhibits bone destruction through competitive occupation of FcÎ³RI and reduced RANKL signalling. Clinical and Translational Immunology, 2020, 9, e1174.	1.7	7
116	Childhood primary large vessel CNS vasculitis: single-centre experience and review of the literature. Clinical and Experimental Rheumatology, 2017, 35 Suppl 103, 213-220.	0.4	7
117	Drug delivery systems as immunomodulators for therapy of infectious disease: Relevance to COVID-19. Advanced Drug Delivery Reviews, 2021, 178, 113848.	6.6	6
118	Biosimilars in pediatric rheumatology and their introduction into routine care. Clinical Immunology, 2020, 216, 108447.	1.4	6
119	Real world treatment of juvenile-onset systemic lupus erythematosus: Data from the UK JSLE cohort study. Clinical Immunology, 2022, 239, 109028.	1.4	6
120	IL10 promoter haplotypes may contribute to altered cytokine expression and systemic inflammation in celiac disease. Clinical Immunology, 2018, 190, 15-21.	1.4	5
121	Vasculitis in Cystic Fibrosis. Frontiers in Pediatrics, 2020, 8, 585275.	0.9	4
122	Cyclic AMP Response Element Modulator-Î± Suppresses PD-1 Expression and Promotes Effector CD4+ T Cells in Psoriasis. Journal of Immunology, 2021, 207, 55-64.	0.4	4
123	Serum protein signatures differentiate paediatric autoimmune/inflammatory disorders. Clinical Immunology, 2021, 229, 108790.	1.4	4
124	Orbital inflammation and colitis in pediatric IgG4-related disease: A case report and review of the literature. European Journal of Rheumatology, 2020, 7, 21-27.	1.3	4
125	Longitudinal analysis of urinary proteins in lupus nephritis â€“ A pilot study. Clinical Immunology, 2022, 236, 108948.	1.4	4
126	Working Towards a Treat-to-Target Protocol in Juvenile Proliferative Lupus Nephritis â€“ A Survey of Pediatric Rheumatologists and Nephrologists in Germany and Austria. Frontiers in Pediatrics, 2022, 10, 851998.	0.9	4

#	Article	IF	Citations
127	Therapeutic approaches to pediatric COVID-19: an online survey of pediatric rheumatologists. Rheumatology International, 2021, 41, 911-920.	1.5	3
128	Approaches to Autoimmune Diseases Using Epigenetic Therapy. , 2018, , 387-405.		2
129	Chronic Non-Bacterial Osteomyelitis. , 2019, , 563-585.		2
130	Is it time to re-think juvenile-onset Rheumatic and Musculoskeletal Diseases? â€“ First steps towards individualised treatments to meet agreed targets. Clinical Immunology, 2021, 223, 108647.	1.4	2
131	Is chronic non-infectious osteomyelitis with mandibular involvement a distinct disease?. Lancet Rheumatology, The, 2021, 3, e90-e92.	2.2	2
132	Editorial: Focusing on T-Cells for Novel Treatments of Systemic Lupus Erythematosus. Frontiers in Immunology, 2021, 12, 744866.	2.2	2
133	Epigenetics and the Regulation of Inflammation. , 2015, , 85-111.		1
134	Acrodermatitis Chronica Atrophicans. Journal of Pediatrics, 2016, 170, 335-335.e1.	0.9	1
135	Interference of canakinumab with commercial IL-1Î² ELISAs. Clinical Immunology, 2019, 205, 6-7.	1.4	1
136	SNPs talk to genes using landlines: long-range chromatin interactions link genetic risk with epigenetic patterns in Takayasu arteritis. Annals of the Rheumatic Diseases, 2019, 78, 1293-1295.	0.5	1
137	Bone Pain in Upper Leg, Hip, Lower Back. , 2019, , 583-590.		1
138	RIP2-deficiency induces inflammation in response to SV40 Large T induced genotoxic stress through altered ROS homeostasis. Clinical Immunology, 2022, 238, 108998.	1.4	1
139	Chorioretinitis in a 7-Year-Old African Girl, Probably Related to JSSc Resolving to Methotrexate Therapy. Klinische Padiatrie, 2011, 223, 92-94.	0.2	0
140	THU0004â€…Camp responsive element modulator (CREM) alpha contributes to decreased NOTCH-1 expression in T cells from patients with systemic lupus erythematosus (SLE). Annals of the Rheumatic Diseases, 2013, 71, 155.1-155.	0.5	0
141	P40â€ƒS100A8/A9 and S100A12 may be biomarkers for juvenile-onset systemic lupus erythematosus. Rheumatology, 2019, 58, .	0.9	0
142	Pharmacoepigenetics of Systemic Lupus Erythematosus. , 2019, , 597-608.		0
143	I017â€ƒThe molecular pathophysiology of CNO and consequences for patient care. Rheumatology, 2019, 58, .	0.9	0
144	FRI0574â€…CLINICAL RESPONSE TO HIGH-DOSE INTRAVENOUS METHYLPREDNISOLONE IN CHILDHOOD AUTOIMMUNE UVEITIS: A RETROSPECTIVE ANALYSIS. , 2019, , .		0

#	Article	IF	Citations
145	SP0187â€…PATHOPHYSIOLOGY AND THERAPEUTIC CONSEQUENCES AUTO-INFLAMMATORY BONE DISORDERS. , 2019, , .		0
146	OP0193â€…CAMP RESPONSE ELEMENT MODULATOR (CREM)A INDUCES DUAL SPECIFICITY PROTEIN PHOSPHATASE (DUSP)4 THROUGH EPIGENETIC REMODELING, PROMOTING IL-17A AND REDUCING IL-2 EXPRESSION IN T CELLS. , 2019, , .		0
147	Chronic Nonbacterial Osteomyelitis. , 2019, , 227-248.		0
148	Antiphospholipid-Syndrom bei Kindern und Jugendlichen. Springer Reference Medizin, 2021, , 1-18.	0.0	0
149	Biosimilars in der pÃdiatrischen Rheumatologie. Springer Reference Medizin, 2021, , 1-6.	0.0	0
150	Comment on: Limited sensitivity and specificity of the ACR/EULAR-2019 classification criteria for SLE in JSLE?: Reply. Rheumatology, 2021, , .	0.9	0
151	1675â€…Real world treatment of juvenile systemic lupus erythematosus (JSLE): evidence from the UK JSLE cohort study. , 2021, , .		0
152	Vaskulitiden bei Kindern und Jugendlichen. Springer Reference Medizin, 2019, , 1-8.	0.0	0
153	Vaskulitiden. Springer Reference Medizin, 2020, , 1123-1130.	0.0	0
154	WS12.06 Hypertonic saline triggers inflammatory responses in human macrophages. Journal of Cystic Fibrosis, 2022, 21, S24.	0.3	0